Overview

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Status:
Recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in our hospital from January 2020 to December 2023 were retrieved. The number of previous treatment lines was not limited. Patients who met the inclusion criteria were screened according to the inclusion and exclusion criteria. Demographic information, clinical characteristics, tumor treatment history, medication regimen, adverse reactions, molecular test results, survival follow-up results and other data were collected. The prospective study : Patients with advanced thyroid cancer who received precise treatment in our hospital from January 2024 to April 2027 were enrolled.
Phase:
Phase 4
Details
Lead Sponsor:
Fudan University
Collaborators:
Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia Medical University
Shanxi Province Cancer Hospital
Treatments:
Antibodies
Dabrafenib
Entrectinib
Immunoglobulins
Lenvatinib
Pralsetinib
Trametinib